VCAM1 and coronary atherosclerosis: Most importantly, the preclinical studies from diabetic individuals with coronary artery atherosclerosis also indicate that immunoreactivity of SREBP-1 is predominantly localized in VCAM-1-positive vascular cells and lipid-rich macrophages of the plaques.